MedTrace Logo

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure

NCT03030235 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 324

Last updated 2022-10-19

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to evaluate the impact of dapagliflozin, as compared with placebo, on heart failure, disease specific biomarkers, symptoms, health status and quality of life in patients with chronic heart failure with preserved systolic function.

Conditions

  • Chronic Heart Failure With Preserved Systolic Function

Interventions

DRUG

Dapagliflozin 10Mg Oral Tablet

Dapagliflozin 10Mg Oral Tablet

DRUG

Dapagliflozin matching placebo

Dapagliflozin matching placebo

Sponsors & Collaborators

  • Saint Luke's Health System

    lead OTHER

Principal Investigators

  • Mikhail Kosiborod, MD · Saint Luke's Mid America Heart Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
119 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2021-08-13
Completion
2021-08-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03030235 on ClinicalTrials.gov